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S U M M A R Y
Objectives: The aim of the current study was to compare the effectiveness of adefovir dipivoxil (ADV)
monotherapy with that of combination ADV and lamivudine (LAM) therapy in the treatment of LAM-
resistant chronic hepatitis B (CHB).
Methods: Publications on the effectiveness of ADV monotherapy versus the combination of ADV and
LAM therapy for the treatment of LAM-resistant CHB were identiﬁed by a search (up to year 2010) of the
PubMed, HealthStar, ScienceDirect, and VIP databases. Biochemical response data (alanine aminotrans-
ferase normalization rate) and virological response data (serum hepatitis B virus DNA undetectable rate)
were extracted and combined to obtain an integrated result.
Results: The literature search yielded 11 articles, six of which reported randomized controlled trials; the
remaining ﬁve reported prospective cohort studies. The summary odds ratio (OR) values of the
biochemical response at 3, 6, 12, and >12 months were 1.60 (p = 0.06), 1.30 (p = 0.18), 1.77 (p = 0.008),
and 3.35 (p < 0.00001), respectively. The summary OR values of the virological response at 3, 6, 12, and
>12 months were 1.46 (p = 0.21), 1.68 (p = 0.04), 1.16 (p = 0.54), and 1.87 (p = 0.01), respectively.
Conclusions: The effectiveness of the combination therapy was not obviously predominant over the
monotherapy in short duration therapies; however, the combination therapy had a great advantage over
monotherapy in both biochemical and virological response when the therapy duration was prolonged to
>12 months.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Chronic hepatitis B (CHB) is prevalent, with an estimated 350
million cases worldwide.1 Despite the availability of vaccines to
immunize people against the disease, CHB remains a major health
problem in many countries because of its high degree of
infectiousness.2,3
Antiviral medication plays an important role in the treatment
of CHB.4,5 Anti-hepatitis B virus (HBV) therapy can postpone the
spread of the disease, enhance patient quality of life, and
prolong the patient’s life span.5 In recent years, the prognosis
and clinical history of chronic HBV infection have been changed
by antiviral therapies.6,7 One such type of antiviral medication,
the nucleotide analogues, are becoming increasingly popular
because they are administered orally, there is an observable
efﬁcacy in the treatment of disease, and the adverse reaction
rate is low.* Corresponding author. Tel.: +86 25 86185038.
E-mail address: cyf990@163.com (Y. Chen).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.11.006Drug resistance is a major problem for nucleotide analogues
during antiviral therapy. Therefore, another drug is usually added
to the current medication, or the ongoing drug is switched to
another medication.8,9 Lamivudine (LAM) was the ﬁrst commonly
used nucleotide analogue. However, LAM resistance in patients is
now prevalent. The second nucleotide analogue introduced to the
market was adefovir dipivoxil (ADV). ADV can effectively inhibit
the replication of HBV DNA and can therefore be used for LAM-
resistant patients. The meta-analysis presented in this paper was
undertaken in order to determine whether adding ADV to ongoing




The retrieval of articles in the English-language literature was
conducted by a search of the ScienceDirect, PubMed, and
HealthStar databases; articles in the Chinese-language literature
were identiﬁed by a VIP database search. Articles published upses. Published by Elsevier Ltd. All rights reserved.
Table 1
Basic information about the study
Study
number
The study [Ref.] Research design The age of
patients
Study duration Treatment protocols Sample
size
1 Yang et al., 2008 [10] RCT l6–62 48 weeks Monotherapy 73
Combination therapy 73
2 Luo 2009 [11] RCT 19–56 1 year Monotherapy 21
Combination therapy 21
3 Zhan et al., 2009 [12] RCT 18–65 72 weeks Monotherapy 42
Combination therapy 38
4 Gaia et al., 2008 [13] Prospective cohort study >18 72 months Monotherapy 29
Combination therapy 23
5 Vassiliadis et al., 2009 [14] RCT >18 60 months Monotherapy 15
Combination therapy 45
6 Rapti et al., 2007 [15] RCT >18 4 years Monotherapy 14
Combination therapy 28
7 Peters et al., 2004 [16] RCT 16–65 48 weeks Monotherapy 19
Combination therapy 20
8 Fung et al., 2007 [17] Prospective cohort study >15 24 months Monotherapy 28
Combination therapy 28
9 Santantonio et al., 2009 [18] Prospective cohort study >18 55 months Monotherapy 30
Combination therapy 30
10 Kim et al., 2005 [19] Prospective cohort study 18–67 24 weeks Monotherapy 18
Combination therapy 28
11 Manolakopoulos et al., 2007 [20] Prospective cohort study >18 48 months Monotherapy 23
Combination therapy 59
RCT, randomized controlled trial.
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combinations of the following keywords: ‘‘Lamivudine’’, ‘‘Adefovir
Dipivoxil’’, and ‘‘Chronic Hepatitis B’’. Titles and abstracts were
screened to determine the relevance of the articles. Next, the
article full-texts were reviewed. Abstracts, case reports, editorials,
and review articles were excluded from the meta-analysis. The
literature search was carried out by two different individuals.
2.2. Inclusion and exclusion criteria
The inclusion criteria for the present study were the following:
(1) all patients with diagnosed CHB, ongoing LAM therapy, and
who had developed LAM resistance, (2) studies comparing the
effectiveness of ADV monotherapy with that of combination ADV
and LAM therapy, (3) randomized controlled trials (RCTs) or
prospective cohort studies, and (4) virological or biochemical
response data.
Exclusion criteria were as follows: case report; review;
editorial; non-comparative study; retrospective study; non-
English or non-Chinese; co-infection with other viruses; liver
transplantation; hepatic cirrhosis; non-LAM resistance; no inter-
vention; usage of other drugs; and other articles irrelevant to the
objectives of the present study.
2.3. Quality assessment and data extraction
The quality of the studies was assessed using the following
factors: (1) deﬁnite description of the methods employed, including
the inclusion criteria for patients, grouping and treatment, follow-up
treatments, end-points, and statistical analyses, and (2) concrete
presentation of results. Only those studies that fulﬁlled the above
quality criteria were included in the meta-analysis.
Basic information about the studies was extracted, such as
author’s name, publication year, research design, study duration,
and sample size (Table 110–20). To determine the effectiveness of
the therapy, biochemical response data (alanine aminotransferases
normalization rate) and virological response data (serum HBV DNA
undetectable rate) were also extracted.
Both quality assessment and data extraction were conducted by
two different individuals.2.4. Statistical analysis
The statistical analysis was conducted using Review Manager 5
software. The outcomes – biochemical response and virological
response at 3, 6, 12, and >12 months after therapy – were
evaluated using odds ratios (OR) and the 95% conﬁdence intervals
(95% CI).
The above software can automatically generate forest plots. The
presence of heterogeneity was observed in the forest plots
generated. At p  0.05, heterogeneity was considered statistically
insigniﬁcant, and the ﬁxed effect model was used in the analysis. At
p < 0.05, heterogeneity was considered statistically signiﬁcant,
and the random effect model was used in the analysis. The ﬁxed
effect model assumes identical treatment effects in the studies,
whereas the random effect model assumes that each study has a
unique treatment effect distributed randomly regarding an
average study treatment effect.
In the forest plots generated, the integrated results are shown to
the right, and the horizontal lines represent conﬁdence intervals.
The horizontal lines are longer when the sampling size is smaller.
The square in the middle of the horizontal line represents the point
estimation value for each study, and the solid diamond symbol
represents the comprehensive effect of these studies. The vertical
line divides the graph into two parts. When the result is
unfavorable, the symbol on the left of the vertical line displays a
better outcome. When the symbol and the vertical line intersect,
no signiﬁcant statistical difference exists between the two
therapies.
2.5. Sensitivity analysis
Sensitivity analyses were conducted from two aspects to
observe the effect of the following indeterminate factors: (1)
Inclusion of RCTs only: only RCTs being included can control the
heterogeneity well, so in the sensitivity analysis we determined
what the outcomes would be if only the 6 RCTs were included. (2)
Analysis using the random effect model as a substitute for the ﬁxed
effect model: the random effect model is typically applied when
the studies included are evidently heterogeneous. In the baseline
research, the ﬁxed effect model was used because of the
Figure 1. Search strategy ﬂow chart and rationale for study exclusion.
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the sensitivity analysis to minimize the potential effect of
heterogeneity.
3. Results
3.1. Study selection and characteristics
The search method identiﬁed 143 articles from PubMed, 77
from ScienceDirect, 114 from HealthStar, and 212 from the VIP
database. Articles with titles obviously not encompassing the
selection criteria were excluded, including 108 from PubMed, 48
from ScienceDirect, 99 from HealthStar, and 191 from VIP. From
the remaining publications, 29 PubMed, 26 ScienceDirect, 9
HealthStar, and 15 VIP articles were excluded based on their
abstracts. The full text of the remaining articles was then read.
Another seven English-language and three Chinese-language
publications were excluded. In total, eight English-language and
three Chinese-language studies were included. Of these 11 studies,
six were RCTs (three each in Chinese and English), and the










3 4 0.48 Fixed effect model 
6 7 0.55 Fixed effect model 
12 7 0.71 Fixed effect model 
>12 (mean 50,
median 52)
6 0.84 Fixed effect model 
OR, odds ratio; 95% CI, 95% conﬁdence interval.screening process is shown in Figure 1, and details of the articles
selected are shown in Table 1.
3.2. Meta-analysis
3.2.1. Biochemical response
From the forest plots (Appendices 1–4), no signiﬁcant statistical
heterogeneity was observed in all the studies in each subgroup.
Therefore, the ﬁxed effect model was used in the analysis. Based on
the OR, 95% CI, and p-values, no signiﬁcant difference was present
between the monotherapy and combination therapy in terms of
biochemical response after 3 and 6 months of therapy. However,
prolonging the duration of therapy to 12 months revealed
signiﬁcant differences between the two therapies (Table 2).
3.2.2. Virological response
From the forest plots (Appendices 5–8), no signiﬁcant statistical
heterogeneity was present in all the studies in each subgroup,
Thus, the ﬁxed effect model was used in the analysis. Based on the
OR, 95% CI, and p-values, no signiﬁcant differences were present





48/132 72/147 1.60 (0.98, 2.61) 0.06
120/218 176/274 1.30 (0.89, 1.89) 0.18
142/217 200/257 1.77 (1.16, 2.70) 0.008















3 2 0.07 Fixed effect model 27/86 45/113 1.46 (0.81, 2.62) 0.21
6 5 0.84 Fixed effect model 57/117 102/170 1.68 (1.02, 2.79) 0.04
12 6 0.61 Fixed effect model 75/146 113/193 1.16 (0.72, 1.88) 0.54
>12 (mean 46, median 48) 7 0.22 Fixed effect model 104/175 177/236 1.87 (1.16, 3.02) 0.01
OR, odds ratio; 95% CI, 95% conﬁdence interval.
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prolonging the therapy duration to >12 months revealed a
signiﬁcant difference between the two therapies (Table 3).
3.3. Sensitivity analysis
3.3.1. Inclusion of RCTs only – biochemical response
In the biochemical response research, three studies were
included at 3 months of therapy, four at 6 months of therapy, ﬁve at
12 months of therapy, and three at >12 months of therapy. All the
p-values of heterogeneity were >0.05, therefore the ﬁxed effect
model was used in the analysis. The summary OR, 95% CI, and p-
values were 1.83 (1.06, 3.16), p = 0.03 at 3 months after therapy;
1.53 (0.97, 2.41), p = 0.07 at 6 months; 1.82 (1.12, 2.95), p = 0.02 at
12 months; and 4.39 (2.04, 9.46), p = 0.0002 at >12 months. The
combination therapy did not show any considerable advantage
during the ﬁrst year of therapy. However when the therapy
duration was extended to 12 months, the combination therapy
appeared to be much more effective than the monotherapy.
3.3.2. Inclusion of RCTs only – virological response
In the virological response research, two studies were included
at 3 months of therapy, three at 6 months of therapy, four at 12
months of therapy, and four at >12 months of therapy. All the p-
values of heterogeneity were >0.05, therefore the ﬁxed effect
model was used in the analysis. The summary OR, 95% CI, and p-
values were 1.46 (0.81, 2.62), p = 0.21 at 3 months; 0.96 (0.52,
1.78), p = 0.90 at 6 months; 1.46 (0.80, 2.63), p = 0.21 at 12 months;
and 2.81 (1.49, 5.30), p = 0.001 at >12 months. No signiﬁcant
differences were found between the two therapies during the ﬁrst
year. However, when the therapy duration was extended to >12
months, the combination therapy seemed to be much more
effective than the monotherapy.
3.3.3. Analysis using the random effect model as a substitute for the
ﬁxed effect model – biochemical response
Analysis using the random effect model produced the following
summary of the OR, 95% CI, and p-values: 1.60 (0.97, 2.62), p = 0.06
at 3 months; 1.30 (0.88, 1.92), p = 0.18 at 6 months; 1.79 (1.17,
2.74), p = 0.007 at 12 months; and 3.40 (1.99, 5.81), p < 0.00001 at
>12 months. The combination therapy did not exhibit any
signiﬁcant advantages during the ﬁrst 6 months of therapy.
However, when the therapy duration was extended to 12
months, the combination therapy appeared to be much more
effective than the monotherapy.
3.3.4. Analysis using the random effect model as a substitute for the
ﬁxed effect model – virological response
Analysis using the random effect model yielded the following
summary of the OR, 95% CI, and p-values: 1.91 (0.51, 7.08), p = 0.34
at 3 months; 1.10 (0.60, 2.00), p = 0.76 at 6 months; 1.17 (0.72,
1.91), p = 0.53 at 12 months; and 1.88 (1.03, 3.44), p = 0.04 at >12
months. No signiﬁcant differences between the combinationtherapy and monotherapy were found. However, there was a
trend showing that when the therapy duration went beyond 12
months, the combination therapy would be much more effective
than the monotherapy.
4. Discussion
4.1. Summary of the analyses
Based on the baseline and sensitivity analyses, prolonging the
duration of therapy to over 12 months results in a more favorable
outcome for the combination therapy compared with the
monotherapy. This result may be partly attributed to the wild-
type HBV that emerges with time after the discontinuation of LAM,
and in the combination therapy group LAM can help in decreasing
the potential development of wild-type HBV. The Clinical Practice
Guidelines for HBV of both the European Association for the Study
of the Liver and the American Association for the Study of Liver
Diseases suggest the addition of adefovir (if tenofovir is not yet
available) for LAM-resistant rescues. This recommendation is
based on the antiviral effect and the risk of multiple drug-resistant
strains. To some extent the current meta-analysis conﬁrms the
above guidelines.
4.2. Limitations
4.2.1. Quality of the studies included
From the 11 articles included in the present study, only six were
RCTs, and no concrete descriptions were given about the methods
of randomization. Five of the selected articles were prospective
cohort studies, which may have more practical importance but will
unavoidably induce heterogeneity. Moreover, the sample size in
the studies included was not sufﬁciently large. Statistically, this
was not persuasive enough to yield conclusive results.
4.2.2. Data extraction
The time units of the results provided in the studies were
different, such as weeks, months, and even years. In the present
research, all units of time were uniﬁed to months. Data were
extracted for 3, 6, 12, and >12 months of therapy. In the extraction
process, 48 and 52 weeks of treatment duration in the different
studies were considered equal to 12 months. However, this
method may also be a source of heterogeneity.
4.2.3. Inclusion criteria
Several variations were included in the articles analyzed. In
some studies, only LAM-resistant patients with hepatitis B e
antigen (HBeAg)-negative CHB were included, whereas in others,
only LAM-resistant patients with HBeAg-positive CHB were
included, and other studies did not specify HBeAg status. This
could also be a source of heterogeneity. However, the heterogene-
ity test results indicated that conducting any subgroup analysis
was not necessary.
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In conclusion, the results show that the effectiveness of both
therapies depends on the duration of therapy. In therapies of
short duration, no considerable predominance was observed for
either therapy. However, extending therapy to more than 12Appendix 1. Forest plot for biochemical response after 3 months of t
Appendix 2. Forest plot for biochemical response after 6 months of t
Appendix 3. Forest plot for biochemical response after 12 months of
Appendix 4. Forest plot for biochemical response after >12 months omonths gave the combination therapy a greater advantage over
monotherapy, both in terms of biochemical and virological
response.
Conﬂict of interest: The current study was completed by the
authors without any support from other organizations. No conﬂict




Appendix 5. Forest plot for virological response after 3 months of therapy.
Appendix 6. Forest plot for virological response after 6 months of therapy.
Appendix 7. Forest plot for virological response after 12 months of therapy.
Appendix 8. Forest plot for virological response after >12 months of therapy.
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